Neumora Therapeutics, Inc. Common Stock (NMRA) Earnings Analysis
Neumora Therapeutics, Inc. Common Stock (NMRA) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it beat with EPS -0.3 USD vs -0.32 USD est (+6.3%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E -1.16.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does NMRA next report earnings?
No confirmed upcoming earnings date is currently scheduled for NMRA. This page updates as the calendar is published.
NMRA earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -0.3 USD | -0.32 USD | +6.3% | Beat |
| 2026-03-16 | -0.35 USD | -0.34 USD | -2.9% | Miss |
| 2025-11-06 | -0.35 USD | -0.34 USD | -2.9% | Miss |
| 2025-05-12 | -0.42 USD | -0.4 USD | -5% | Miss |
| 2025-03-03 | -0.37 USD | -0.46 USD | +19.6% | Beat |
Beat rate: 2/5 (40%) over reported quarters with consensus data.
NMRA valuation and analyst view
| Trailing P/E | -1.16 |
|---|---|
| Trailing EPS | -1.2364 USD |
| Price / book | 3.92 |
| Dividend yield | 0.00% |
| Market cap | 0.29B |
| Analyst consensus | Buy (6 buy / 1 hold / 2 sell) |
| Avg price target | 4.5 USD |
Related research pages
Frequently asked questions
When is Neumora Therapeutics, Inc. Common Stock (NMRA)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for NMRA. This page updates as the calendar is published.
Did NMRA beat earnings last quarter?
In its 2026-05-07 report, NMRA posted EPS of -0.3 USD versus a -0.32 USD estimate — a beat of 6.3%.
What is NMRA's earnings track record?
Over the last 5 reported quarters with consensus data, NMRA beat estimates 2 times (40%).
What is NMRA's current P/E ratio and EPS?
NMRA trades at a trailing P/E of -1.16 on trailing EPS of -1.2364014410247286 USD.
What do analysts rate NMRA?
Analyst consensus is "Buy" across 9 ratings (0 strong buy, 6 buy, 1 hold, 2 sell, 0 strong sell). Average 12-month price target: 4.5 USD.